On February 6, Huadong Medicine Co.Ltd(000963) (000963) announced that Sinclair, a wholly-owned subsidiary of the company in the UK, acquired 100% equity of viora, an energy source medical and beauty device company.
● it is reported that viora company was founded in 2005 and headquartered in New York, USA. It is an international medical beauty company focusing on medical beauty non-invasive and minimally invasive energy source equipment. It has innovative technologies such as core, SVC and PCR. It has an advanced product portfolio using laser, intense pulsed light, RF, high-pressure jet, micro crystal skin grinding and other technologies to provide high-quality Cost effective non-invasive and minimally invasive solutions. The products are used in anti-aging, body and face shaping and other fields. Viora has sales operations in more than 60 countries / regions around the world, with more than 10000 global institutional users.
At present, viora mainly has five listed energy source medical and beauty equipment products, including reactiontm for body and face shaping and skin firming, medical and beauty multi-functional operation platform “V-series” products integrating radio frequency (RF), intense pulsed light (IPL), laser and other energy sources, and enerjet products using JVR needle free minimally invasive high-pressure injection technology, Pristinetm, a diamond microcrystalline dermabrasion equipment, adopts infusiontm of ionwave electroporation introduction technology.
Huadong Medicine Co.Ltd(000963) said that it has preliminarily formulated the market strategy in China according to viora’s existing products. For example, reactiontm, its core product, adopts viora’s multi frequency RF core technology and is equipped with three different treatment handles. It has been approved by the US FDA and obtained the registration certificate of class III medical devices from the State Drug Administration (nmpa) in 2015. After the equity delivery of viora is completed, Huadong Medicine Co.Ltd(000963) plans to quickly integrate reactiontm into China’s self operated sales team, Quickly carry out market promotion.
It is worth mentioning that Huadong Medicine Co.Ltd(000963) proposed the concept of “V women tech” for the first time, using the world’s advanced medical and aesthetic technology to focus on the field of women’s scientific and technological nursing and create a high-end product pipeline. The V-series multifunctional integrated operation platform of viora company acquired this time can be equipped with multiple types of energy sources of laser / RF / intense pulse light at the same time, which can provide comprehensive solutions for face and body, and realize all-round care for female customers, including beauty care for face, body and private parts. In addition, viora has the industry-leading R & D strength of energy source equipment. For the field of professional women’s nursing, viora has rich reserves of products under research. It has covered professional instruments and equipment including women’s neck, chest and private parts for shaping, tightening, lifting and rejuvenation of women’s body parts. It is expected to be listed in overseas markets after the second half of 2022.
Huadong Medicine Co.Ltd(000963) said that this transaction is another important global strategic layout in the field of medical and American energy source equipment after Sinclair wholly acquired high tech, a Spanish energy source medical and American equipment company, in February 2021. Viora’s existing technologies and products such as intense pulsed light, microcrystalline dermabrasion and high-pressure jet are effectively complementary to Sinclair EBD business product pipeline, realizing the full layout of energy source medical and American device products and basically realizing the coverage of mainstream technologies of energy source devices.
Huadong Medicine Co.Ltd(000963) said that after the acquisition, the Spanish and Bulgarian teams of Sinclair EBD business will effectively integrate with the existing management, production, R & D and other departments of viora company to further improve the operation and management efficiency of Sinclair EBD business. Viora’s good brand reputation, perfect market service staffing, complete marketing management system and extensive market resources in the U.S. market will also become an effective entry point for Sinclair EBD business to further expand the U.S. market.
● according to statistics, after the completion of this transaction, Huadong Medicine Co.Ltd(000963) will have more than 30 products in the field of non-invasive + minimally invasive medical beauty all over the world, including 20 products listed at home and abroad and more than 10 global innovative products under research. The product portfolio covers non-surgical mainstream medical beauty fields such as facial filling, catgut embedding, skin management, body shaping, hair removal and private repair, A comprehensive product cluster has been formed, with the number and coverage of products in the forefront of the industry. Among them, a number of potential products are expected to be listed and sold at home and abroad in 2022, which will bring new growth momentum to the company’s global medical and American business.
Lv Liang, chairman of the board of directors of Huadong Medicine Co.Ltd(000963) said that viora’s products have differentiated competitive advantages. This transaction further expands the company’s innovative product pipeline of medical beauty, conforms to the company’s international development strategy of medical beauty, and helps to continuously consolidate and improve the company’s comprehensive competitiveness in the field of medical beauty. In the future, the company will continue to make steady progress in accordance with the established strategy of “global operation layout, double cycle operation and development”, strengthen the international industrial expansion with Sinclair, a wholly-owned subsidiary of the UK, as the global medical and beauty operation center, and adhere to the diversified business models such as independent research and development, external cooperation and equity investment to bring the world-class Medical beauty products with high gold content in science and technology have been introduced into China one after another, adhering to the self-supporting model, relying on the company’s professional clinical registration and marketing promotion team to help the rapid commercialization of international high-quality products. Gradually realize the company’s global strategic layout of medical beauty, and strive to build Sinclair into a world-class high-end innovative medical beauty enterprise.
\u3000\u3000
